Skip to main content

Research Repository

Advanced Search

CLL Research

People Involved

Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors (2025)
Journal Article
Molica, S., & Allsup, D. (2025). Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors. Cancers, 17(1), Article 119. https://doi.org/10.3390/cancers17010119

Chronic lymphocytic leukemia (CLL) treatment has evolved from traditional chemotherapy to targeted therapies, such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors with significant improvements in survival rates and a transformation of CLL into a... Read More about Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.

High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition (2024)
Journal Article
James, D., Green, S., Molica, S., & Allsup, D. (2024). High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. Case Reports in Hematology, 2024, Article 1813512. https://doi.org/10.1155/2024/1813512

The coexistence of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient is exceedingly rare, with only a few cases reported in the literature. Here, we report a patient with CML who, having achieved a major molecu... Read More about High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study (2024)
Presentation / Conference Contribution
C, T., Minga, E., Karakatsoulis, G., Albi, E., Alcoceba, M., Allsup, D., Bacchiarri, F., Besikli-Dimou, S., Chatzileontiadou, S., Collado, R., Davis, Z., Dimou, M., Donaldson, D., Efstathopoulou, M., Galimberti, S., Galitzia, A., Gimeno, E., Guarente, V., Hatzimichael, E., Hernandez-Rivas, J.-A., …Scarfo, L. (2024, December). Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study. Presented at American Society of Hematology 66th Annual Meeting, San Diego, California

Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia (2024)
Journal Article
Molica, S., Allsup, D., & Giannarelli, D. (online). Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia. American Journal of Hematology, https://doi.org/10.1002/ajh.27437

The emergence of Bruton's tyrosine kinase (BTK) inhibitors marked a significant advancement in chronic lymphocytic leukemia (CLL) management, especially for high-risk patients. 1 Ibrutinib, the pioneering BTK inhibitor, has undergone extensive study.... Read More about Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.